Table 1.
Patient demographics and baseline clinical characteristics
| Characteristic | Adolescents | |
|---|---|---|
| Vehicle (n = 45) | 1.5% ruxolitinib cream (n = 92) | |
| Age, median (range), years | 14.0 (12–17) | 15.0 (12–17) |
| Female, n (%) | 23 (51.1) | 59 (64.1) |
| Race, n (%)a | ||
| White | 33 (73.3) | 72 (78.3) |
| Black | 11 (24.4) | 13 (14.1) |
| Asian | 1 (2.2) | 3 (3.3) |
| Other | 0 | 4 (4.3) |
| Region, n (%) | ||
| North America | 31 (68.9) | 64 (69.6) |
| Europe | 14 (31.1) | 28 (30.4) |
| BSA, mean (SD), % | 10.8 (5.3) | 10.4 (6.0) |
| EASI, mean (SD) | 8.2 (5.0) | 8.0 (5.2) |
| IGA, n (%) | ||
| 2 | 13 (28.9) | 23 (25.0) |
| 3 | 32 (71.1) | 69 (75.0) |
| Itch NRS score, mean (SD)b | 4.5 (2.4) | 4.3 (2.4) |
| ≥ 2, n (%) | 36 (80.0) | 72 (78.3) |
| ≥ 4, n (%) | 24 (53.3) | 50 (54.3) |
| PROMIS sleep-related impairment score (8a), mean (SD)c | 14.9 (4.9) | 16.3 (6.0) |
| ≥ 6, n (%)d | 41 (91.1) | 89 (96.7) |
| PROMIS Sleep Disturbance score (8b), mean (SD)e | 16.7 (5.0) | 17.1 (5.4) |
| ≥ 6, n (%)d | 38 (84.4) | 87 (94.6) |
| Duration of disease, median (range), years | 11.4 (2.9–16.9) | 13.0 (2.4–17.9) |
| Facial involvement, n (%) | 19 (42.2) | 41 (44.6) |
| Number of flares in last 12 months, mean (SD) | 6.7 (6.8) | 6.2 (6.9) |
BSA body surface area, EASI Eczema Area and Severity Index, IGA Investigator’s Global Assessment, NRS numerical rating scale, PROMIS Patient-Reported Outcomes Measurement Information System
aPatient self-identification
bData missing from six patients at baseline (vehicle, n = 4; 1.5% ruxolitinib cream, n = 2)
cData missing from seven patients at baseline (vehicle, n = 4; 1.5% ruxolitinib cream, n = 3)
dMinimum score for PROMIS 8a and 8b in this study was 8
eData missing from 12 patients at baseline (vehicle, n = 7; 1.5% ruxolitinib cream, n = 5)